The alternative asset managers have begun talking to investment banks on strategic options including a sale of the Virginia-based financial services company specializing in innovative cash management and deposit solutions.
THE LATEST NEWS ON MERGERS & ACQUISITIONS, CAPITAL MARKETS AND TECH TRENDS
PHOTO: BLACKSTONE
Blackstone, Warburg weighing $12B sale of fintech IntraFi
The alternative asset managers have begun talking to investment banks on strategic options including a sale of the Virginia-based financial services company specializing in innovative cash management and deposit solutions. Read here
Coach parent Tapestry pulls $8.5B bid for Capri
The New York-based luxury fashion company is terminating its deal to buy the the Michael Kors owner following a legal hurdle, ending their effort to create a US luxury giant to compete with European players.Read here
PHOTO: AJAY SURESH
Private-equity owners of Diligent explore $7B sale
Insight Partners, Blackstone, and Clearlake have started interviewing investment banks as they prepare to launch a sale process for the the corporate-governance software maker early next year.Read here
PHOTO: DILIGENT
Instructure’s $4.8B
take-private completed
Global investment firms KKR and Dragoneer Investment have finalized their acquisition of the Utah-based provider of education technology including the Canvas learning management platform.Read here
The South Korean conglomerate has decided to execute a stock repurchase over a one-year period to boost shareholder value, after shares plunged earlier this week. Read here
Blackstone eyes stake in Haldiram at $8B valuation
The global investment firm has dropped plans to acquire a majority stake in the snacks business of the Indian company, and is now discussing purchase of a 20% share. Read here
KKR raises offer for Fuji Soft to 1 yen above Bain’s
The New York-based investment firm increased its price for the Japanese software developer above a rival bid by the Boston buyout firm, winning the board's backing. Read here
Evotec gets $2.1B takeover interest from Halozyme
The Nasdaq-listed biotech firm has submitted a non-binding proposal to acquire the German drug discovery and development company for €11 per share.Read here